CD molecules | Other protein targets | IUPHAR/BPS Guide to PHARMACOLOGY

CD molecules C

Unless otherwise stated all data on this page refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).

Overview

Show »« Hide

Cluster of differentiation refers to an attempt to catalogue systematically a series of over 300 cell-surface proteins associated with immunotyping. Many members of the group have identified functions as enzymes (for example, see CD73 ecto-5'-nucleotidase) or receptors (for example, see CD41 integrin, alpha 2b subunit). Many CDs are targeted for therapeutic gain using antibodies for the treatment of proliferative disorders. A full listing of all the Clusters of Differentiation proteins is not possible in the Guide to PHARMACOLOGY; listed herein are selected members of the family targeted for therapeutic gain.

Targets

CD1d molecule Show summary »« Hide summary More detailed page

CD2 C Show summary »« Hide summary More detailed page

CD3e C Show summary »« Hide summary More detailed page

CD4 Show summary »« Hide summary More detailed page

CD6 C Show summary »« Hide summary More detailed page

Fc fragment of IgG receptor IIIa / CD16A Show summary »« Hide summary More detailed page

Target Id	3017
Nomenclature	Fc fragment of IgG receptor IIIa
Systematic nomenclature	CD16A
Previous and unofficial names	Fc receptor, IgG, low affinity IV \| Fc receptor \| FCγRIIIa \| FcRIIIA \| low affinity immunoglobulin gamma Fc region receptor III-A
Genes	FCGR3A (Hs), Fcgr4 (Mm), Fcgr3a (Rn)
Ensembl ID	ENSG00000203747 (Hs), ENSMUSG00000059089 (Mm), ENSRNOG00000024382 (Rn)
UniProtKB AC	P08637 (Hs), A0A0B4J1G0 (Mm)

CD19 Show summary »« Hide summary More detailed page

CD20 (membrane-spanning 4-domains, subfamily A, member 1) C Show summary »« Hide summary More detailed page

SIGLEC2 (CD22) Show summary »« Hide summary More detailed page

Target Id	2786
Nomenclature	CD22
Common abbreviation	SIGLEC2
Previous and unofficial names	B-lymphocyte cell adhesion molecule \| sialic acid binding Ig-like lectin 2 \| SIGLEC-2
Genes	CD22 (Hs)
Ensembl ID	ENSG00000012124 (Hs)
UniProtKB AC	P20273 (Hs)

CD28 Show summary »« Hide summary More detailed page

Target Id

2863

Nomenclature

CD28

Previous and unofficial names

cluster of differentiation 28 | CD28 antigen (Tp44)

Genes

CD28 (Hs), Cd28 (Mm), Cd28 (Rn)

Ensembl ID

ENSG00000178562 (Hs), ENSMUSG00000026012 (Mm), ENSRNOG00000010283 (Rn)

UniProtKB AC

P10747 (Hs), P31041 (Mm), P31042 (Rn)

Antibodies

lulizumab pegol (Binding) pK_d 9.3 – 9.4 [28]

Comment

CD28 is expressed on the surface of T cells and is required for the co-stimulatory signal essential for the activation and survival of T cells. CD28 acts in concert with the T cell receptor to stimulate cytokine release. The B7 proteins CD80 and CD86 on the surface of antigen presenting cells bind CD28.
As a drug target, CD28 modulation is being investigated as a treatment for autoimmume conditions.

SIGLEC3 (CD33) C Show summary »« Hide summary More detailed page

CD36 molecule Show summary »« Hide summary More detailed page

Target Id	3104
Nomenclature	CD36 molecule
Previous and unofficial names	collagen type I receptor, thrombospondin receptor \| platelet glycoprotein 4 \| SCARB3 \| fatty acid translocase (FAT)
Genes	CD36 (Hs), Cd36 (Mm), Cd36 (Rn)
Ensembl ID	ENSG00000135218 (Hs), ENSMUSG00000002944 (Mm), ENSRNOG00000040108 (Rn)
UniProtKB AC	P16671 (Hs), Q08857 (Mm)
Comment	CD36 is a multi-functional protein that acts as a receptor for broad range of ligands including thrombospondin, fibronectin, collagen, amyloid β, oxidised low-density lipoprotein, anionic phospholipids, long-chain fatty acids and bacterial diacylated lipopeptides. Ligand binding to CD36 induces cellular activities that are involved in angiogenesis, inflammatory responses, fatty acid metabolism and oral fat perception and it directly mediates cytoadherence of Plasmodium falciparum parasitised erythrocytes.

CD37 (CD37 molecule) Show summary »« Hide summary More detailed page

Target Id	3010
Nomenclature	CD37 molecule
Common abbreviation	CD37
Previous and unofficial names	CD37 antigen \| tetraspanin 26 \| TSPAN26
Genes	CD37 (Hs), Cd37 (Mm), Cd37 (Rn)
Ensembl ID	ENSG00000104894 (Hs), ENSMUSG00000030798 (Mm), ENSRNOG00000020699 (Rn)
UniProtKB AC	P11049 (Hs), P31053 (Rn)
Comment	The CD37 protein has 4 hydrophobic transmembrane domains, and it belongs to the tetraspanin (TSPAN) protein family (HGNC family ID 768) [7,30]. It is expressed solely by cells of the immune system, and is involved in the regulation of immune responses [20], cell development, activation, growth and motility [7,30].

CD38 Show summary »« Hide summary More detailed page

CD47 Show summary »« Hide summary More detailed page

Target Id	2943
Nomenclature	CD47
Previous and unofficial names	CD47 antigen \| CD47 antigen (Rh-related antigen, integrin-associated signal transducer) \| CD47 antigen (Rh-related antigen \| integrin associated protein IAP \| integrin-associated signal transducer \| MER6
Genes	CD47 (Hs), Cd47 (Mm), Cd47 (Rn)
Ensembl ID	ENSG00000196776 (Hs), ENSMUSG00000055447 (Mm), ENSRNOG00000001964 (Rn)
UniProtKB AC	Q08722 (Hs), Q61735 (Mm), P97829 (Rn)

CD52 C Show summary »« Hide summary More detailed page

NCAM1 (neural cell adhesion molecule 1 (CD56)) Show summary »« Hide summary More detailed page

P-selectin (CD62) Show summary »« Hide summary More detailed page

Target Id	3103
Nomenclature	P-selectin (CD62)
Previous and unofficial names	CD62P \| GMP140 \| granule membrane protein 140kD \| PADGEM \| pSEL
Genes	SELP (Hs)
Ensembl ID	ENSG00000174175 (Hs)
UniProtKB AC	P16109 (Hs)
Comment	P-selectin is a cell adhesion molecule that is produced by activated endothelial cells and platelets. Its endogenous ligand is selectin P ligand (SELPLG).

CD66e (CEACAM5) Show summary »« Hide summary More detailed page

Target Id

2836

Nomenclature

CD66e (CEACAM5)

Previous and unofficial names

CEA | carcinoembryonic antigen-related cell adhesion molecule 5 | carcinoembryonic antigen related cell adhesion molecule 5

Genes

CEACAM5 (Hs)

Ensembl ID

ENSG0000010538 (Hs)

UniProtKB AC

P06731 (Hs)

Antibodies

labetuzumab (Binding)

labetuzumab govitecan (Binding)

CD74 Show summary »« Hide summary More detailed page

Target Id	2840
Nomenclature	CD74
Previous and unofficial names	HLA-DR-gamma \| Ia-associated invariant chain \| invariant polypeptide of major histocompatibility complex, class II antigen-associated \| CD74 molecule, major histocompatibility complex, class II invariant chain \| Cd74 molecule, major histocompatibility complex, class II invariant chain \| CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated) \| CD74 antigen (invariant polypeptide of major histocompatibility complex
Genes	CD74 (Hs), Cd74 (Mm), Cd74 (Rn)
Ensembl ID	ENSG00000019582 (Hs), ENSMUSG00000024610 (Mm), ENSRNOG00000018735 (Rn)
UniProtKB AC	P04233 (Hs), P04441 (Mm), P10247 (Rn)
Comment	CD74 is expressed by many patient-derived multiple myeloma specimens and cell lines [4], making CD74 a promising target for therapeutic intervention in B cell malignancies.

CD79B Show summary »« Hide summary More detailed page

Target Id	2852
Nomenclature	CD79B
Previous and unofficial names	immunoglobulin-associated beta \| IGB \| CD79b molecule, immunoglobulin-associated beta \| Cd79b molecule, immunoglobulin-associated beta
Genes	CD79B (Hs), Cd79b (Mm), Cd79b (Rn)
Ensembl ID	ENSG00000007312 (Hs), ENSMUSG00000040592 (Mm), ENSRNOG00000011917 (Rn)
UniProtKB AC	P40259 (Hs), P15530 (Mm)
Comment	CD79B is a component of the multimeric B lymphocyte antigen receptor (along with CD79A and a membrane-bound antibody that acts as the antigen recognition moiety).

CD80 C Show summary »« Hide summary More detailed page

LILRB1 (leukocyte immunoglobulin like receptor B1 (CD85j)) Show summary »« Hide summary More detailed page

Target Id	2973
Nomenclature	leukocyte immunoglobulin like receptor B1 (CD85j)
Common abbreviation	LILRB1
Previous and unofficial names	ILT2 \| leucocyte Ig-like receptor B1 \| leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1 \| LIR-1 \| LIR1 \| MIR-7 \| myeloid inhibitory receptor 7 \| PIR-B \| PIRB
Genes	LILRB1 (Hs)
Ensembl ID	ENSG00000104972 (Hs)
UniProtKB AC	Q8NHL6 (Hs)

LILRA4 (leukocyte immunoglobulin like receptor A4 (CD85g)) Show summary »« Hide summary More detailed page

Target Id	2896
Nomenclature	leukocyte immunoglobulin like receptor A4 (CD85g)
Common abbreviation	LILRA4
Previous and unofficial names	leucocyte Ig-like receptor A4 \| ILT7 \| immunoglobulin-like transcript 7
Genes	LILRA4 (Hs)
Ensembl ID	ENSG00000239961 (Hs)
UniProtKB AC	P59901 (Hs)

CD86 C Show summary »« Hide summary More detailed page

FcαRI (Fc fragment of IgA receptor / CD89) Show summary »« Hide summary More detailed page

Target Id	2991
Nomenclature	Fc fragment of IgA receptor
Systematic nomenclature	CD89
Common abbreviation	FcαRI
Genes	FCAR (Hs), Fcar (Rn)
Ensembl ID	ENSG00000186431 (Hs), ENSRNOG00000027855 (Rn)
UniProtKB AC	P24071 (Hs)

semaphorin 4D (CD100) Show summary »« Hide summary More detailed page

Target Id	2883
Nomenclature	semaphorin 4D (CD100)
Previous and unofficial names	SEMAJ \| M-sema-G \| sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4D \| sema domain
Genes	SEMA4D (Hs), Sema4d (Mm), Sema4d (Rn)
Ensembl ID	ENSG00000187764 (Hs), ENSMUSG00000021451 (Mm)
UniProtKB AC	Q92854 (Hs), O09126 (Mm)
Comment	Semaphorin 4D is a member of a family of soluble and membrane-bound proteins, originally defined as axonal-guidance factors [10]. A soluble form of the protein (sSEMA4D) is generated by proteolytic cleavage of the extracellular domain [32]. Semaphorin 4D is prediminantly expressed on human leukocytes and plays a functional role in the immune system [14,29].

endoglin (CD105) Show summary »« Hide summary More detailed page

CTLA-4 (cytotoxic T-lymphocyte-associated protein 4 (CD152)) C Show summary »« Hide summary More detailed page

Target Id

2743

Nomenclature

cytotoxic T-lymphocyte-associated protein 4 (CD152)

Common abbreviation

CTLA-4

Previous and unofficial names

ICOS | cytotoxic T-lymphocyte-associated protein 4

Genes

CTLA4 (Hs), Ctla4 (Mm), Ctla4 (Rn)

Ensembl ID

ENSG00000163599 (Hs), ENSMUSG00000026011 (Mm), ENSRNOG00000010336 (Rn)

UniProtKB AC

P16410 (Hs), P09793 (Mm)

Antibodies

ipilimumab (Binding) pK_d >9.0 [13]

tremelimumab (Binding) pK_d 8.9 [16]

KIR3DL2 (CD158K) Show summary »« Hide summary More detailed page

Target Id	3067
Nomenclature	KIR3DL2 (CD158K)
Previous and unofficial names	killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 1 \| killer cell immunoglobulin-like receptor \| cl-5 \| Kirl1 (Mm) \| nkat4 \| nkat4a
Genes	KIR3DL2 (Hs), Kir3dl1 (Mm)
Ensembl ID	ENSG00000240403 (Hs), ENSMUSG00000031424 (Mm)
UniProtKB AC	P43630 (Hs)

NKG2A (killer cell lectin like receptor C1 (CD159a) / CD159a) Show summary »« Hide summary More detailed page

Target Id	2849
Nomenclature	killer cell lectin like receptor C1 (CD159a)
Systematic nomenclature	CD159a
Common abbreviation	NKG2A
Previous and unofficial names	killer cell lectin-like receptor subfamily C \| killer cell lectin-like receptor subfamily C, member 1 \| NKG2-1/B activating NK receptor \| NKG2-A
Genes	KLRC1 (Hs), Klrc1 (Mm), Klrc1 (Rn)
Ensembl ID	ENSG00000134545 (Hs), ENSMUSG00000030167 (Mm)
UniProtKB AC	P26715 (Hs)

SIRPA (CD172a) Show summary »« Hide summary More detailed page

LAG3 (CD223) / CD223 Show summary »« Hide summary More detailed page

Target Id	2932
Nomenclature	LAG3 (CD223)
Systematic nomenclature	CD223
Genes	LAG3 (Hs), Lag3 (Mm), Lag3 (Rn)
Ensembl ID	ENSG00000089692 (Hs), ENSMUSG00000030124 (Mm), ENSRNOG00000021334 (Rn)
UniProtKB AC	P18627 (Hs), Q61790 (Mm)
Comment	LAG3 is a negative regulator of T cells (a check point immunomodulator). It is evolutionarily related to CD4 and both proteins share conserved structual motifs, despite only being ~20% homologous at the amino acid level. Divergent biological functions likely reside in their cytoplasmic domains which contain unique structural and molecular differences.

B7-H3 (CD276) Show summary »« Hide summary More detailed page

ICOS (CD278) Show summary »« Hide summary More detailed page

Target Id	2939
Nomenclature	ICOS (CD278)
Previous and unofficial names	inducible T-cell costimulator \| activation-inducible lymphocyte immunomediatory molecule \| AILIM \| CVID1 \| inducible costimulator
Genes	ICOS (Hs), Icos (Mm), Icos (Rn)
Ensembl ID	ENSG00000163600 (Hs), ENSMUSG00000026009 (Mm), ENSRNOG00000046196 (Rn)
UniProtKB AC	Q9Y6W8 (Hs), Q9WVS0 (Mm), Q9R1T7 (Rn)

PD-1 (programmed cell death 1 (CD279)) C Show summary »« Hide summary More detailed page

CD300a C Show summary »« Hide summary More detailed page

LAIR1 (leukocyte associated immunoglobulin like receptor 1 (CD305)) Show summary »« Hide summary More detailed page

Target Id	2974
Nomenclature	leukocyte associated immunoglobulin like receptor 1 (CD305)
Common abbreviation	LAIR1
Previous and unofficial names	Lair-1 \| leukocyte-associated Ig-like receptor 1 \| leukocyte-associated immunoglobulin-like receptor 1
Genes	LAIR1 (Hs), Lair1 (Mm), Lair1 (Rn)
Ensembl ID	ENSG00000167613 (Hs), ENSMUSG00000055541 (Mm), ENSRNOG00000027733 (Rn)
UniProtKB AC	Q6GTX8 (Hs), Q8BG84 (Mm), P0C1X9 (Rn)

CS1 (CD319) Show summary »« Hide summary More detailed page

Target Id	2850
Nomenclature	CS1 (CD319)
Previous and unofficial names	CRACC \| CS1-L \| CD2-like receptor-activating cytotoxic cells
Genes	SLAMF7 (Hs), Slamf7 (Mm), Slamf7 (Rn)
Ensembl ID	ENSG00000026751 (Hs), ENSMUSG00000038179 (Mm), ENSRNOG00000023209 (Rn)
UniProtKB AC	Q9NQ25 (Hs), Q8BHK6 (Mm)
Comment	CS1 is a member of the signalling lymphocyte activation molecule (SLAM) receptor family. CS1 is a membrane glycoprotein primarily expressed on plasma cells. Homophilic interaction (ie interaction with itself) of CS1 induces B cell proliferation and autocrine cytokine secretion, thus playing a role in various immune functions.

TIM3 (CD366) Show summary »« Hide summary More detailed page

Comments

Show »« Hide

References

Show »« Hide

1. Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, Shimada K, Chan CH, Tutt A, Beers SA et al.. (2011) Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood, 117 (17): 4519-29. [PMID:21378274]

2. Bernstein ID. (2000) Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia, 14 (3): 474-5. [PMID:10720144]

3. Bolt S, Routledge E, Lloyd I, Chatenoud L, Pope H, Gorman SD, Clark M, Waldmann H. (1993) The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur. J. Immunol., 23 (2): 403-11. [PMID:8436176]

4. Burton JD, Ely S, Reddy PK, Stein R, Gold DV, Cardillo TM, Goldenberg DM. (2004) CD74 is expressed by multiple myeloma and is a promising target for therapy. Clin. Cancer Res., 10 (19): 6606-11. [PMID:15475450]

5. Caron PC, Co MS, Bull MK, Avdalovic NM, Queen C, Scheinberg DA. (1992) Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res., 52 (24): 6761-7. [PMID:1458463]

6. Carven GJ, Van Eenennaam H, Dulos GJ. (2010) Antibodies to human programmed death receptor PD-1. Patent number: US20100266617. Assignee: Organon NV. Priority date: 13/06/2008. Publication date: 21/10/2010.

7. Charrin S, le Naour F, Silvie O, Milhiet PE, Boucheix C, Rubinstein E. (2009) Lateral organization of membrane proteins: tetraspanins spin their web. Biochem. J., 420 (2): 133-54. [PMID:19426143]

8. da Silva AJ, Brickelmaier M, Majeau GR, Li Z, Su L, Hsu YM, Hochman PS. (2002) Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. J. Immunol., 168 (9): 4462-71. [PMID:11970990]

9. De Weers M, Graus Y, Oprins J, Parren P, Van De Winkel J, Van Vugt M. (2010) Antibodies Against Cd38 For Treatment Of Multiple Myeloma. Patent number: US7829673. Assignee: Genmab A/S. Priority date: 23/03/2005. Publication date: 09/11/2010.

10. Giger RJ, Hollis 2nd ER, Tuszynski MH. (2010) Guidance molecules in axon regeneration. Cold Spring Harb Perspect Biol, 2 (7): a001867. [PMID:20519341]

11. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Dyer MJ, Catovsky D. (1998) Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk. Res., 22 (2): 185-91. [PMID:9593475]

12. Goldstein G. (1987) Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation. Transplant. Proc., 19 (2 Suppl 1): 1-6. [PMID:3105134]

13. Halk EL, Korman AJ, Lonberg N. (2001) Human ctla-4 antibodies and their uses. Patent number: WO2001014424. Assignee: Medarex Inc. Priority date: 24/08/1999. Publication date: 01/03/2001.

14. Hall KT, Boumsell L, Schultze JL, Boussiotis VA, Dorfman DM, Cardoso AA, Bensussan A, Nadler LM, Freeman GJ. (1996) Human CD100, a novel leukocyte semaphorin that promotes B-cell aggregation and differentiation. Proc. Natl. Acad. Sci. U.S.A., 93 (21): 11780-5. [PMID:8876214]

15. Hall RD, Gray JE, Chiappori AA. (2013) Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer. Cancer Control, 20 (1): 22-31. [PMID:23302904]

16. Hanson DC, Neveu MJ, Mueller EE, Hanke JH, Gilman SC, Davis CG, Corvalan JR. (2004) Human monoclonal antibodies to CTLA-4. Patent number: US6682736 B1. Assignee: Abgenix, Inc., Pfizer Inc.. Priority date: 22/12/1998. Publication date: 27/01/2004.

17. Kline J, Gajewski TF. (2010) Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr Opin Investig Drugs, 11 (12): 1354-9. [PMID:21154117]

18. Korman AJ, Srinivasan M, Wang C, Selby MJ, Chen B, Cardarelli JM. (2006) Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics. Patent number: WO2006121168. Assignee: Ono Pharmaceutical Co. Priority date: 09/05/2005. Publication date: 02/03/2015.

19. Latek R, Fleener C, Lamian V, Kulbokas 3rd E, Davis PM, Suchard SJ, Curran M, Vincenti F, Townsend R. (2009) Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation. Transplantation, 87 (6): 926-33. [PMID:19300198]

20. Levy S, Shoham T. (2005) The tetraspanin web modulates immune-signalling complexes. Nat. Rev. Immunol., 5 (2): 136-48. [PMID:15688041]

21. Linke R, Klein A, Seimetz D. (2010) Catumaxomab: clinical development and future directions. MAbs, 2 (2): 129-36. [PMID:20190561]

22. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. (1991) CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med., 174 (3): 561-9. [PMID:1714933]

23. Liu Q. (2013) Fully human antibodies against human cd20. Patent number: WO2013007052. Assignee: Qingfa Liu. Priority date: 13/07/2011. Publication date: 17/01/2013.

24. Mitchell P. (2002) First biotech drug to treat psoriasis. Nat. Biotechnol., 20 (7): 640-1. [PMID:12089534]

25. Reslan L, Dalle S, Herveau S, Perrial E, Dumontet C. (2014) Apoptotic induction by anti-CD20 antibodies in chronic lymphocytic leukemia: comparison of rituximab and obinutuzumab. Leuk. Lymphoma, 55 (1): 188-90. [PMID:23537278]

26. Shitara K, Niwa R, Natsume A. (2011) Recombinant antibody composition. Patent number: US7923538 B2. Assignee: Kyowa Hakko Kirin Co., Ltd. Priority date: 22/07/2005. Publication date: 12/04/2011.

27. Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M, Horak ID, Hansen HJ, Goldenberg DM. (2004) Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin. Cancer Res., 10 (8): 2868-78. [PMID:15102696]

28. Suchard SJ, Davis PM, Kansal S, Stetsko DK, Brosius R, Tamura J, Schneeweis L, Bryson J, Salcedo T, Wang H et al.. (2013) A monovalent anti-human CD28 domain antibody antagonist: preclinical efficacy and safety. J. Immunol., 191 (9): 4599-610. [PMID:24081989]

29. Suzuki K, Kumanogoh A, Kikutani H. (2008) Semaphorins and their receptors in immune cell interactions. Nat. Immunol., 9 (1): 17-23. [PMID:18087252]

30. van Deventer SJ, Dunlock VE, van Spriel AB. (2017) Molecular interactions shaping the tetraspanin web. Biochem. Soc. Trans., 45 (3): 741-750. [PMID:28620035]

31. Vicente Rabaneda EF, Herrero-Beaumont G, Castañeda S. (2013) Update on the use of abatacept for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol, 9 (7): 599-621. [PMID:23899231]

32. Zhu L, Bergmeier W, Wu J, Jiang H, Stalker TJ, Cieslak M, Fan R, Boumsell L, Kumanogoh A, Kikutani H et al.. (2007) Regulated surface expression and shedding support a dual role for semaphorin 4D in platelet responses to vascular injury. Proc. Natl. Acad. Sci. U.S.A., 104 (5): 1621-6. [PMID:17244710]

How to cite this family page

Database page citation:

CD molecules. Accessed on 04/04/2020. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=852.

Concise Guide to PHARMACOLOGY citation:

Alexander SPH, Kelly E, Mathie A, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Buneman OP, Cidlowski JA, Christopoulos A, Davenport AP, Fabbro D, Spedding M, Striessnig J, Davies JA; CGTP Collaborators. (2019) The Concise Guide to PHARMACOLOGY 2019/20: Introduction and Other Protein Targets. Br J Pharmacol. 176 Issue S1: S1-S20.

CD molecules C

Overview

Targets

Comments

Further reading

References

How to cite this family page